Review
Nature Reviews Drug Discovery 3, 479-487 (June 2004) | doi:10.1038/nrd1415
GSK3 inhibitors: development and therapeutic potential
Philip Cohen1 & Michel Goedert2 About the authors
Abstract
Glycogen synthase kinase-3 (GSK3) was initially identified more than two decades ago as an enzyme involved in the control of glycogen metabolism. In recent years it has been shown to have key roles in regulating a diverse range of cellular functions, which have prompted efforts to develop GSK3 inhibitors as therapeutics. Here, we describe the biology of GSK3 relevant to its potential as a target for diabetes and neurodegenerative diseases, and discuss progress in the development of GSK3 inhibitors.
- View At a Glance
Author affiliations
- MRC Protein Phosphorylation Unit, School of Life Sciences, University of Dundee, Dundee, DD1 5EH, UK.
- MRC Laboratory of Molecular Biology, Cambridge CB2 2QH, UK.
Correspondence to: Philip Cohen1 Email: p.cohen@dundee.ac.uk
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated.
NEWS AND VIEWS
Alzheimer's disease Mental plaque removalNature News and Views (22 May 2003)
Flies tangle with tauNature Medicine News and Views (01 Jun 2002)
See all 5 matches for News And ViewsRESEARCH
Decreased nuclear β-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3β conditional transgenic miceThe EMBO Journal Article (15 Jan 2001)
See all 41 matches for Research
